 Home > Active Ingredient News > Drugs Articles > O drug encounters patent disputes again!

O drug encounters patent disputes again!

 Last Update: 2022-04-28
 Source: Internet
 Author: User

Tags

patent issues

pharmaceutical supply chain

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Bristol-Myers Squibb filed a lawsuit in the District Court of Delaware, suing AstraZeneca's blockbuster oncology drug Imfinzi for infringing at least eight patents related to Opdivo
.

It is reported that the eight patents are '505, '507, '299, '714, '594, '595, '596 and '092
.
In the lawsuit, Bristol-Myers Squibb said AstraZeneca willfully infringed those patents by marketing Imfinzi as a "late-stage development" treatment

In late 2014, Opdivo was launched globally for the treatment of advanced melanoma
.
Since then, Bristol-Myers Squibb has expanded its indications to include renal cell carcinoma, non-small cell lung cancer, lymphoma, urothelial carcinoma, head and neck cancer,

etc.

It is worth noting that this is not the first time that Bristol-Myers Squibb has filed a patent lawsuit against its competitor in the PD-(L)1 field
.
As early as 2017, Merck paid Bristol-Myers Squibb as much as $625 million to resolve the Keytruda patent issue and agreed to pay royalties based on Keytruda sales until 2026

Patent disputes are not uncommon in the pharmaceutical industry
.
Just last week, AstraZeneca paid $775 million to Roche Chugai Pharmaceutical to settle all patent disputes related to the C5 inhibitor Ultomiris

Reference source:

2.
Merck? Check.
Roche? Check.
Now Bristol Myers Squibb wants AstraZeneca to pay for PD-L1 patents

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Methyl-L-alanine3913-67-5

CAS No.: 3913-67-5

Industrial Grade

$1-1.04/KG FOB

High Purity 99% PEG MGF CAS 108174-48-7 Customized Peptides from China OUDA

CAS No.: 108174-48-7

Pharmacy Grade

$2-2.6/G FOB

Wholesales Purity 99 Peptides Powder Sema Tirz Retatrutide 5mg/10mg/15mg to Door From China

CAS No.: 2023788-19-2

Pharmacy Grade

$150-180/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.